fda compounding semaglutide warning september 2025 letters Compounded " semaglutide" is not FDA-approved FDA issues 30 warning letters – Best Semaglutide Options for 2026:

Visible weight-loss results often become more noticeable between 8 and 12 weeks, though timelines vary from person to person

Weight loss typically begins within the first month, although the rate varies depending on the dose, diet, exercise, and individual metabolism

A lower negotiated price is expected to begin in 2027

Rosenstock reported that body weight loss of almost 17% was achieved with the 8 mg and 12 mg doses at week 36, without showing a plateau

Storage expectations and shipping presentation are reviewed carefully for temperature-conscious peptide fulfillment

Glucagon-like peptide-1 (GLP-1) receptor agonists are temperature-sensitive biological medications that require careful storage to maintain their therapeutic efficacy